Haematology

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Anchored in the science of human plasma, ADMA Biologics operates as a fully vertically integrated commercial biopharmaceutical company applying patented immunotechnology to develop, manufacture, and commercialise plasma-derived biologics for patients with serious immunological disorders. Listed on NASDAQ (ticker: ADMA) and headquartered in Boca Raton, Florida, the company controls each stage of its supply chain, from plasma collection through fill-finish manufacturing and medical affairs, a model that sets it apart from conventional pharmaceutical manufacturers dependent on external plasma suppliers. Commercial Portfolio and Plasma Collection ADMA's marketed products include ASCENIV, an intravenous immunoglobulin (IVIG) indicated for primary humoral immunodeficiency in adults and adolescents; BIVIGAM, a broad-spectrum IVIG therapy; and Nabi-HB, a hyperimmune globulin targeting hepatitis B. These products are manufactured at the company's FDA-licensed facility in Boca Raton. Plasma supply is secured through ADMA BioCenters, its own network of plasma collection centres operating across the United States, which feed proprietary immunotechnology fractionation processes downstream. Contract development and manufacturing services extend the company's commercial reach, allowing third-party biopharmaceutical partners to access ADMA's specialised biologics processing infrastructure. Scientific direction is guided by a dedicated Scientific Advisory Board, and the medical affairs function supports clinician engagement, publications, and advocacy for patients living with primary immunodeficiency disease. Further information is available at admabiologics.com.

Grounded in a proprietary boron chemistry platform , AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology , with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases , particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

Founded by Paul Janssen in Beerse, Belgium in 1953 and now operating as the pharmaceutical division of Johnson Johnson, Janssen Global stands among the world's foremost research-driven pharmaceutical organisations. The business concentrates scientific and commercial resources on discovering, developing and delivering transformative medicines across oncology, immunology, infectious diseases and neuroscience, with a particularly strong record in haematological malignancies and autoimmune conditions. Therapeutic Focus and Pipeline Depth Janssen's approved portfolio illustrates the breadth of its therapeutic reach. In oncology and haematology , Darzalex (daratumumab) has become a standard-of-care option across multiple myeloma lines, while Imbruvica (ibrutinib), developed in collaboration with AbbVie, is approved across several B-cell malignancies. Zytiga (abiraterone acetate) remains a recognised treatment in metastatic prostate cancer. In immunology, Stelara (ustekinumab) and Tremfya (guselkumab) address moderate-to-severe plaque psoriasis and other inflammatory conditions. The neuroscience portfolio includes Spravato (esketamine), a nasal-spray formulation approved for treatment-resistant depression in adults. HIV and tuberculosis medicine reflects a long-standing infectious disease commitment carried through products such as Edurant (rilpivirine) and contribution to combination regimens used globally. Global Operations and Research Infrastructure Research and development hubs span Beerse, Spring House (Pennsylvania), La Jolla (California), Leiden in the Netherlands and Shanghai, supporting a pipeline that extends from early discovery through late-stage clinical programmes. Janssen works alongside academic medical centres, biotech partners and health systems to accelerate access. As a central component of Johnson Johnson's pharmaceutical segment, operating under the J J Innovative Medicine banner from 2023, the organisation benefits from the group's global manufacturing network, regulatory infrastructure and substantial annual R D investment. Its pharmaceutical pipeline spans both small molecules and large biologics, with active programmes in areas such as solid tumours, multiple sclerosis and pulmonary arterial hypertension. Further information is available at janssen.com.

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology , haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.